Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

The Wray masterclass for budding millionaires

Article Abstract:

Nigel Wray is an investor in real estate, rugby, soccer and small companies. He started work in a merchant bank, and lost money in real estate in 1974. He bought Fleet Street Letter, a newsletter which included stock tips, in 1975. This was a successful investment, and the company was floated on the Alternative Investment Market. Wray also set up a real estate partnership with Nick Leslau. He is a director and stockholder of Nottingham Forest Football Clubs, and is the owner of the Saracens rugby club.

Author: Sefton, Caroline
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
Real Estate, Real Estate and Rental and Leasing, Management, Real estate industry, Businessmen, Wray, Nigel

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Sage

Article Abstract:

UK business management software firm Sage is suffering from a maturing market for accounting software and its shares now look overvalued. Sage is also seeing rising competition in the US, and weak demand for customer relationship management software.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Prepackaged software, Software Publishers, Business Software Pkgs (Micro), Computer software industry, Software industry, Business management software, Suites (Software), Securities, Sage Group PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Similar abstracts:
  • Abstracts: The gathering storm. Debating fair value. Accounting for reality
  • Abstracts: Are the boom times over? Why auditors are being reduced to chocolate eclairs. Strength in numbers?
  • Abstracts: The real interest rate puzzle. The real interest rates puzzle
  • Abstracts: The road to empowerment. Trusting your instincts. Sites for sore eyes
  • Abstracts: The second wave in kinase cancer drugs. Conflicting signals on US accelerated approvals. Knockout drug screens
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.